Intra-Cellular Therapies (ITCI) Set to Announce Quarterly Earnings on Tuesday

Intra-Cellular Therapies (NASDAQ:ITCI) is set to issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.14. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The company had revenue of $132.10 million during the quarter, compared to analyst estimates of $135.97 million. During the same period in the previous year, the business posted ($0.45) earnings per share. The firm’s quarterly revenue was up 50.3% compared to the same quarter last year. On average, analysts expect Intra-Cellular Therapies to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Intra-Cellular Therapies Stock Up 0.7 %

NASDAQ:ITCI opened at $69.26 on Monday. Intra-Cellular Therapies has a 1 year low of $45.50 and a 1 year high of $84.89. The stock’s 50 day simple moving average is $69.16 and its two-hundred day simple moving average is $65.56.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Royal Bank of Canada reissued an “outperform” rating and set a $86.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 3rd. Robert W. Baird increased their price objective on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Cantor Fitzgerald restated an “overweight” rating and set a $120.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, April 24th. Needham & Company LLC boosted their price target on Intra-Cellular Therapies from $82.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, April 22nd. Finally, Bank of America increased their price target on shares of Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.17.

Insider Buying and Selling at Intra-Cellular Therapies

In related news, CFO Lawrence J. Hineline sold 13,337 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.43, for a total transaction of $925,987.91. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Intra-Cellular Therapies news, CEO Sharon Mates sold 20,565 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the completion of the sale, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at approximately $68,490,649.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Lawrence J. Hineline sold 13,337 shares of Intra-Cellular Therapies stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $69.43, for a total transaction of $925,987.91. The disclosure for this sale can be found here. Insiders sold 168,487 shares of company stock valued at $11,364,950 in the last 90 days. Company insiders own 3.40% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.